Stem Cell Researchers Appalled As Judge Blocks Loosened Guidelines
Executive Summary
The National Institutes of Health, trade groups and the stem cell research community reacted swiftly and in united fashion condemning an Aug. 23 federal court decision that blocks a broad range of work being done with human embryonic stem cells, and leaves projects in progress scrambling for new sources of funding
You may also be interested in...
Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Teva Wins Ruling On Copaxone Patents
Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Teva Wins Ruling On Copaxone Patents
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. Earlier stage biotechs are trying to turn their platforms into research revenue as they look to non-profit, government, and private funding sources to advance their preclinical therapeutic programs. Whatever the model, worries abound that the financial woes of the next couple of years could blunt hard-earned momentum.